Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection Pharmaceutical Investing
Veklury® Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients Pharmaceutical Investing
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies Pharmaceutical Investing
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC Pharmaceutical Investing
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline Pharmaceutical Investing
U.S. FDA Accepts Biologics License Application for Pfizer's Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review Pharmaceutical Investing
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO for Post-exposure Prophylaxis for Prevention of COVID-19 Pharmaceutical Investing
Adjuvant Opdivo Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial Pharmaceutical Investing
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer Pharmaceutical Investing
